PDCD1 and cancer: Some features of anti-PD-1 and anti-PD-L1 monoclonal antibodies, such as low tissue permeability, immune-related adverse effects, and high cost, means that better predictive biomarkers are needed so that they are only used to treat the patients most likely to benefit from alternative ways to treat cancer.